Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEvacizumab plus Trifluridine/tipiracil bi-weekly vs conventional in mCRC (GERCOR G-124 BETWEEN)
2024-520128-27-00Phase 2Authorised
- Sponsor
- GERCOR
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab and trifluridine + tipiracil in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by GERCOR. Primary endpoint: Grade 3–4 neutropenia incidence. Planned start Oct 2025; status: authorised.
02
Drugs
bevacizumabtrifluridine + tipiracil
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-520128-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520128-27-00.